The U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday ...

GAITHERSBURG, Md. - Emergent BioSolutions Inc. (NYSE: EBS), a pharmaceutical company with a market capitalization of approximately $510 million, has acquired exclusive commercial rights for KLOXXADO® ...

on Tuesday announced that it has entered into an agreement to obtain exclusive commercial rights in the U.S. and Canada for KLOXXADO or naloxone HCl Nasal Spray from Hikma Pharmaceuticals.

HCL Tech Shares: Stocks tumble over 9% after Q3 earnings (Image: Reuters) HCL Tech Share Price: HCL Technologies saw its shares take a sharp plunge on Tuesday January 14. The stock began trading ...

HCL Technologies shares dropped 9.23% after the company reported a 6% net profit growth for Q3 at Rs 4,591 crore. Revenue rose to Rs 29,890 crore. New deal bookings reached $2.1 billion. Analysts ...

Hikma Pharmaceuticals PLC, the multinational pharmaceutical group, has entered an exclusive commercial partnership with Emergent BioSolutions for the sale of KLOXXADO naloxone HCl nasal spray 8 mg in ...

Alongside over-the-counter NARCAN ® Nasal Spray 4 mg, prescription KLOXXADO ® (naloxone HCl) Nasal Spray 8 mg will expand Emergent's ability to distribute multiple life-saving opioid overdose ...

NARCAN® Naloxone HCl Nasal Spray 4 mg is the first FDA-approved, over-the-counter (OTC) 4 mg naloxone product for the emergency treatment of opioid overdose. NARCAN® Nasal Spray is not a ...

About NARCAN® Nasal SprayNARCAN® Naloxone HCl Nasal Spray 4 mg is the first FDA-approved, over-the-counter (OTC) 4 mg naloxone product for the emergency treatment of opioid overdose.

Analysts noted that despite delivering a solid financial performance led by a sharp uptick in deal wins, both TCS and HCL Tech faced pressure due to higher expectations on the Street. India's ...

Since using black market nasal tanning spray, Harper has had facial flushes, acne, and more freckles. The illegal spray can have serious side effects, according to the Therapeutic Goods ...

Hikma will continue producing its 8 mg naloxone HCl nasal spray in its Columbus, Ohio manufacturing facility and will provide it to Emergent as its exclusive commercial partner. This partnership ...